Premium
LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐ HODGKIN LYMPHOMA TREATED WITH BISPECIFIC ANTIBODY BLINATUMOMAB IN A PHASE I TRIAL
Author(s) -
Dufner V.,
Sayheli C.,
Gelbrich G.,
Bargou R.,
Goebeler M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.136_2630
Subject(s) - blinatumomab , medicine , lymphoma , oncology , refractory (planetary science) , antibody , cd19 , immunology , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom